Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC
Authors:
- 28 August 2019
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 145 (10) , 2613-2624
Abstract
Purpose To determine the frequency of co-occurring genes in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation and the predictive effect of co-mutations on the efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs). Methods 54 patients with advanced NSCLC were tested for 422 clinically relevant genes by next-generation sequencing (NGS) before treatment. Among them, patients with EGFR mutation received first-line treatment of EGFR-TKIs. Progression-free survival (PFS) and objective response rate (ORR) were evaluated using Kaplan–Meier methods and compared between two groups using log-rank test. Results Among 24 EGFR mutant and 30 EGFR wild-type patients, co-mutation rate was lower in patients with EGFR mutation (62.5% [15/24] vs 93.3% [28/30], p = 0.005). There was lower frequency for co-alterations in BRAF (0% [0/24] vs 20% [7/30], p = 0.033), NF1 (4.2% [1/24] vs 30% [9/30], p = 0.038) and RAS–RAF–MAPK pathway genes (16.6% [4/24] vs 56.7% [17/30], p = 0.003) in EGFR mutation group. 24 patients with EGFR mutation received first-line treatment of gefitinib or erlotinib, with an ORR of 83.3% and a median PFS of 12.3 months (95% CI 10.00–14.60). Co-mutation was associated with shorter median PFS (10.2 months [95% CI 5.20–15.20] vs 15.3 months [95% CI 12.09–15.81]; HR 0.29 [95% CI 0.10–0.82]; p = 0.014) in EGFR mutation cohort. Among patients with EGFR mutation and distant metastasis, median PFS was decreased in those with co-mutations (6.3 months [95% CI 3.25–9.35] vs 22.0 months[95% CI 12.10–31.90]; HR 0.12 [95% CI 0.00–5.87]; p = 0.007) and frequency of PIK3CA (0% [0/12] vs 41.7% [5/12], p = 0.037) and PI3K/AKT/mTOR pathway genes (0% [0/12] vs 50% [6/12], p = 0.014) was lower. Conclusion The presence of co-mutations was lower in the EGFR mutation patients and reduces the efficacy of EGFR-TKI, especially in patients with distant metastases. Lower frequency of co-mutation in PIK3CA and PI3K/AKT/mTOR pathway genes may be responsible for promoting metastasis and limiting the efficacy of EGFR-TKIs.Keywords
Funding Information
- Postdoctoral Scientific Research Developmental Fund provided by the Administration Office of Heilongjiang Postdoctoral Program (Grant No. LBH-Q16143)
- Wu Jieping Medical Foundation (Grant No.320.6750.18050)
This publication has 35 references indexed in Scilit:
- Frequency of actionable alterations in epidermal growth factor receptor (EGFR) wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR)Journal of Thoracic Disease, 2018
- Increased expression of miR‐641 contributes to erlotinib resistance in non‐small‐cell lung cancer cells by targeting NF1Cancer Medicine, 2018
- Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancersNature Genetics, 2017
- Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase InhibitorsClinical Cancer Research, 2017
- Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF CohortJournal of Thoracic Oncology, 2015
- PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasionProceedings of the National Academy of Sciences, 2015
- Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung CancerCancer Discovery, 2014
- Trimmomatic: a flexible trimmer for Illumina sequence dataBioinformatics, 2014
- EGF Receptor Activates MET through MAPK to Enhance Non–Small Cell Lung Carcinoma Invasion and Brain MetastasisCancer Research, 2013
- A framework for variation discovery and genotyping using next-generation DNA sequencing dataNature Genetics, 2011